Skip to main content

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Active, not recruiting · Phase 3 · NCT06191744

Conditions: Follicular Lymphoma (FL)

At a glance

Research payments reported, 2025
$2.9M
U.S. investigators named
42
Sites paid
47
Planned or actual enrollment
1,095

About the trial

Sponsor
Genmab (with AbbVie)
Tested
Epcoritamab (drug), Prednisone (drug), Rituximab (drug), Lenalidomide (drug), Doxorubicin (drug), Vincristine (drug), Cyclophosphamide (drug), Obinutuzumab (drug), Bendamustine (drug)
Dates
Started 2024-02-05; completion 2037-11
Results posted
Not yet

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participa…

From ClinicalTrials.gov, last updated 2026-08-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $2.9M in research payments for this study in 2025 (285 payments).

Products named: Epkinly

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.